Wegovy Gains Approval for Treating Obesity in Adolescents
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 designed to modulate heme biosynthesis by limiting glycine uptake.
Pegunigalsidase alfa is a long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate.
The recalled product was distributed between October 26, 2021 and August 10, 2022.
The approval was based on data from the phase 3 ILLUMINATE-C study that included 21 dialysis-independent and -dependent patients with PH1.
Leniolisib is a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially antineoplastic activities.
Velmanase alfa is a recombinant form of human alpha-mannosidase intended to provide or supplement natural alpha-mannosidase.
The safety profile of Orkambi was found to be similar in patients aged 1 to less than 2 years compared with those 2 years of age and older.
Pompe disease is a rare, degenerative muscle disorder caused by mutations in the acid alpha-glucosidase gene, which leads to the abnormal buildup of glycogen.
Xenpozyme is a hydrolytic lysosomal sphingomyelin-specific enzyme replacement therapy designed to replace deficient or defective ASM.